In the Boardroom - Teva Pharmaceutical Industries


Popular Filters

226 to 250 of 274 results

Teva and OncoGenex update on prostate cancer drug development; loss widens at latter


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals…

BiotechnologycustirsenFinancialLicensingOncoGenexPharmaceuticalResearchTeva Pharmaceutical Industries

Opportunities for Pharma in narcolepsy


The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Teva Pharma strong sales growth helped by acquisitions


Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) reported fourth-quarter 2011 results…

CephalonFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Knighthood for GlaxoSmithKline’s Andrew Witty; Teva succession plan


Andrew Witty, chief executive of UK drug giant GlaxoSmithKline (LSE: GSK) has been awarded a Knighthood…

GenericsGlaxoSmithKlineManagementPharmaceuticalTeva Pharmaceutical Industries

Ring in generics in 2012 and beyond, says Zacks Equity Research


The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (Nasdaq:…

Dr Reddy's LaboratoriesGenericsMarkets & MarketingNorth AmericaPatentsRanbaxy LaboratoriesSandozTeva Pharmaceutical IndustriesWatson Pharmaceuticals

OPKO Health buys API developer


Miami, USA-based OPKO Health (NYSE: OPK), which is controlled by Israeli generics giant Teva Pharmaceutical…

FineTech PharmaceuticalGenericsMergers & AcquisitionsOPKO HealthTeva Pharmaceutical Industries

Teva to make massive share buy-back; expects $22 billion sales for 2011


Israel-based generic drugs giant Teva Pharmaceutical Industries (Nasdaq: TEVA) has announced it plans…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Acino buys more Cephalon/Mepha businesses


Swiss branded and generic drugmaker Acino Pharma (SIX: ACIN) and Israel’s Teva Pharmaceutical Industries…

Acino PharmaCephalonGenericsMephaMergers & AcquisitionsTeva Pharmaceutical Industries

Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers


After one year on the market, share of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod),…

AvonexBiogen IdecCopaxoneGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalTeva Pharmaceutical IndustriesTysabri

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint


Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

Teva to continue selling Viagra generic in Russia


Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation…

DynamicoEuropeGenericsMarkets & MarketingPatentsPfizerPharmaceuticalReproductiveTeva Pharmaceutical IndustriesViagra

Generics giant Teva posts 3rd-qtr 2011 sales rise but net income down 13%


The world’s largest generic drugs maker, Teva Pharmaceutical Industries (Nasdaq: TEVA), has reported…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst


Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon


As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Acino pays 80 million euros for Cephalon’s Middle East and African business


Switzerland-based generic and branded drugmaker Acino (SIX: ACIN) says it has reached agreement to acquire…

Acino PharmaCephalonGenericsMergers & AcquisitionsPharmaceuticalRest of the WorldTeva Pharmaceutical Industries

Teva gets EU clearance for Cephalon acquisition; negative review on Azilect


Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA)…

AzilectCephalonMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTeva Pharmaceutical Industries

US antitrust body OKs Teva's acquisition of Cephalon, but with divestments


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US Federal Trade Commission…

CephalonGenericsLegalMergers & AcquisitionsNorth AmericaPar PharmaceuticalsPharmaceuticalProvigilTeva Pharmaceutical Industries

Generic drugmakers step up presence in Russia, with Dr Reddy’s and Teva planning expansions


Indian pharmaceutical manufacturers are accelerating their expansion into the Russian market. Following…

Dr Reddy's LaboratoriesEuropeFinancialGenericsMarkets & MarketingTeva Pharmaceutical Industries

Teva buys out partner Kowa’s interest in Japanese JV for $150 million


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world’s largest generic drugmaker,…

Asia-PacificGenericsKowa PharmaceuticalsMergers & AcquisitionsTeva Pharmaceutical Industries

Teva invests $7.5 million in Cocrystal Discovery for novel hepatitis C antiviral


In a further move to boost its non-generics activities, Israel’s Teva Pharmaceutical Industries…

Anti-viralsCocrystal DiscoveryLicensingMergers & AcquisitionsPharmaceuticalRegulationTeva Pharmaceutical Industries

Teva ups stake in CureTech to 75% following positive clinical results in lymphoma


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an…

CureTechGenericsMergers & AcquisitionsOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

226 to 250 of 274 results

Back to top